This new treatment option can redefine how we approach RRMM treatment by giving healthcare providers a regimen with improvement in PFS and OS and a well-characterized safety profile
The licensed intellectual property covers methods and designs for CAR constructs engineered to function in myeloid cell populations
Their findings, published in the journal Nature, reveal that the spines’ unique porous internal structure allows them to convert water movement into measurable electrical signals
A next-generation, cell-based immunotherapy, CAR-T therapy engineers a patient’s own immune cells to detect and destroy cancer
Fenebrutinib has the potential to become the first and only high-efficacy oral, brain-penetrant treatment for both RMS and PPMS, showing a profound benefit on relapsing and progressive disease biology
The partnership will focus on the ongoing SYNERGY-101 randomized Phase 2 trial for first-line
Sugemalimab, developed using CStone’s OmniRat transgenic platform, is a fully human IgG4 monoclonal antibody designed to minimize immunogenicity and toxicity
The move follows encouraging Phase I data and a series of regulatory wins from the U.S. Food and Drug Administration
The study will test the company’s lead product, ZI-MA4-1, in patients with advanced solid cancers
If approved, DTX401 would be the first treatment to address the disease at its root cause
Subscribe To Our Newsletter & Stay Updated
